Projects per year
Personal profile
Biography
Professor Howard Gurney is the Director of Clinical Trials and Head of the Cancer Program for the Faculty of Medicine and Health Sciences at Macquarie University and Senior Staff Specialist in Medical Oncology at Westmead Hospital.
Dr Gurney has a firm background in clinical research and has subspecialty interests in urogenital cancers including prostate, bladder, testis and kidney cancer.
He has been the principal investigator for over 150 clinical trials and has over 150 per-reviewed publications in genitourinary cancers and pharmacogenomics, including recent papers in the New Engl J Med, Lancet and Lancet Oncology. Current research interests also include the pharmacogenomics and therapeutic monitoring of chemotherapy and targeted therapies and he has published widely in this area. He is regarded as an authority on mechanisms for safe dosing of anticancer agents and has held research grants and has written a number of invited editorials on these topics.
Fingerprint
Dive into the research topics where Howard Gurney is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Litespark: CTU A Multicenter, Open-label, Randomized, Phase 1/2 Study of Belzutifan in Combination with Palbociclib Versus Belzutifan Monotherapy in Participants with Advanced Renal Cell Carcinoma
Gurney, H., Chapman, N. & Chester, C.
3/08/22 → 18/07/27
Project: Research
-
9785-CL-0123: CTU: A Phase 2 Open-label Extension Study for Subjects with Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Gurney, H., Chester, C. & Chapman, N.
6/07/22 → 20/03/27
Project: Research
-
YH002004: CTU A multicenter, open-label, phase I dose escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of YH002 in combination with YH001 in subjects with advanced solid tumors
Gurney, H., Chester, C. & Chapman, N.
2/05/22 → 18/04/27
Project: Research
-
HP518-CS-001: A Phase 1 open-label study to assess the safety, pharmacokinetics and anti-tumor activity of oral HP518 in patients with metastatic castration-resistant prostate cancer
Gurney, H. & Chapman, N.
17/01/22 → 13/12/26
Project: Research
-
A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib plus rucaparib in patients with metastatic castration-resistant prostate cancer
Pook, D., Geynisman, D. M., Carles, J., de Braud, F., Joshua, A. M., Pérez-Gracia, J. L., Pérez, C. L., Shin, S. J., Fang, B., Barve, M., Maruzzo, M., Bracarda, S., Kim, M., Kerloeguen, Y., Gallo, J. D., Maund, S. L., Harris, A., Huang, K-C., Poon, V., Sutaria, D. S., & 1 others, 1 Sept 2023, In: Clinical Cancer Research. 29, 17, p. 3292-3300 9 p.Research output: Contribution to journal › Article › peer-review
-
Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN Bladder 100 trial After ≥2 years of follow-up
Powles, T., Park, S. H., Caserta, C., Valderrama, B. P., Gurney, H., Ullén, A., Loriot, Y., Sridhar, S. S., Sternberg, C. N., Bellmunt, J., Aragon-Ching, J. B., Wang, J., Huang, B., Laliberte, R. J., Di Pietro, A. & Grivas, P., 1 Jul 2023, In: Journal of Clinical Oncology. 41, 19, p. 3486-3492 9 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile6 Citations (Scopus)3 Downloads (Pure) -
Avelumab first-line maintenance plus best supportive care (BSC) vs. BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Asian subgroup analysis
Lee, J-L., Desai, C., Park, S. H., Tsuchiya, N., Su, P. J., Chan, T. T. W., Gurney, H., Gao, S., Wang, J., Sandner, R., di Pietro, A. & Eto, M., May 2023, In: Urologic Oncology: Seminars and Original Investigations. 41, 5, p. 256.e17-256.e25 9 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile1 Citation (Scopus)5 Downloads (Pure) -
Avelumab first-line maintenance therapy for advanced urothelial carcinoma: comprehensive clinical subgroup analyses from the JAVELIN Bladder 100 Phase 3 trial
Grivas, P., Park, S. H., Voog, E., Caserta, C., Gurney, H., Bellmunt, J., Kalofonos, H., Ullén, A., Loriot, Y., Sridhar, S. S., Yamamoto, Y., Petrylak, D. P., Sternberg, C. N., Gupta, S., Huang, B., Costa, N., Laliberte, R. J., di Pietro, A., Valderrama, B. P. & Powles, T., Jul 2023, In: European Urology. 84, 1, p. 95-108 14 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile4 Citations (Scopus)5 Downloads (Pure) -
Dual-energy x-ray absorptiometry assessment of bone health in Australian men with prostate cancer commencing androgen deprivation therapy
Hamid, M. F., Hayden, A., Moujaber, T., Turner, S., Gurney, H., Grossmann, M. & Wong, P., 20 Feb 2023, In: Medical Journal of Australia. 218, 3, p. 126-130 5 p.Research output: Contribution to journal › Article › peer-review
Open Access